Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J adds HealthMedia to new wellness and prevention business

This article was originally published in Clinica

Executive Summary

In a move that establishes its new wellness and prevention business, Johnson & Johnson has acquired HealthMedia, a company specialising in web-based behaviour change technology. Ann Arbor, Michigan-based HealthMedia develops technology for providing what it calls “web-based coaching” for wellness, disease management, behavioural health, and medication adherence. J&J claims that HealthMedia’s technology has been proven to improve cost savings for health plans and employers. J&J says that the purchase of HealthMedia is an initial step in the creation of the new business, which will explore medical solutions before the onset of illness in order to “avoid more costly health care expenses later”. Financial terms of the acquisition were not disclosed.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT041763

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel